New video just out on youtube for the presentation that Bill gave at the recent Sachs Neuroscience Innovation Forum (link below).
He seemed a bit rusty, but generally a good preso.
Couple of key points I took out of it....
- the final DSMB safety analysis will be “in a month or two”
- confident that the efficacy design is appropriate based on the first DSMB analysis
- full results reading out in “May/June”
- they’ve been approached by others for additional indications using xanamem
- current target market for mild Alzheimer’s is US$7.5B based on 1.5m patients. Bill alludes to the upside if you include Prodromol and At Risk markets which have numbers of 4m and 25m, respectively. Even penetrating only 10% of those markets would be massive given that there are almost 20 times more potential users than mild AD.
- Forums
- ASX - By Stock
- ACW
- Sachs Forum Presentation Video
Sachs Forum Presentation Video
-
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACW (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.0¢ |
Change
-0.003(4.11%) |
Mkt cap ! $188.4M |
Open | High | Low | Value | Volume |
7.6¢ | 7.7¢ | 6.7¢ | $633.5K | 8.823M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 49997 | 7.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.1¢ | 114484 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 49997 | 0.070 |
3 | 424336 | 0.069 |
4 | 351290 | 0.068 |
3 | 257482 | 0.067 |
5 | 484968 | 0.065 |
Price($) | Vol. | No. |
---|---|---|
0.071 | 114484 | 2 |
0.072 | 166938 | 2 |
0.073 | 170000 | 2 |
0.074 | 215700 | 3 |
0.075 | 569327 | 7 |
Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
Featured News
ACW (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online